Physician profile
Fenny Zen
NPI 1982268678
$4,230.80
in general payments reported to CMS, 2019-2025
28 companies · $31.07 in 2025
The $31.07 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $11.24 · 2021: $157 · 2022: $1,052 · 2023: $1,330 · 2024: $1,650 · 2025: $31.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,011.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,010.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $772.87 | 2022-2024 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $682.40 | 2022-2025 | Ubrelvy, Vraylar, Qulipta |
| Lilly USA, LLC | $522.09 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Exact Sciences Corporation | $319.38 | 2023-2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $274.22 | 2021-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $227.27 | 2022-2024 | Jardiance, Synjardy, Tradjenta |
| Novo Nordisk INC | $177.57 | 2020-2024 | Ozempic, Rybelsus |
| Phathom Pharmaceuticals, INC. | $175.08 | 2024 | Voquezna |
| Pfizer INC. | $165.51 | 2022-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $141.76 | 2022 | |
| Astellas Pharma US INC | $141.35 | 2022-2024 | Veozah, Myrbetriq |
| Azurity Pharmaceuticals, INC. | $96.88 | 2023-2024 | Edarbyclor, Edarbyclor, Edarbi |
| Sanofi-Aventis U.S. LLC | $90.28 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $79.64 | 2022-2023 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $54.35 | 2022-2023 | Eliquis |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $46.20 | 2022 | |
| Organon LLC | $42.40 | 2023 | Nexplanon |
| Octapharma USA, INC. | $41.03 | 2021 | |
| Merck Sharp & Dohme LLC | $30.28 | 2024 | Gardasil 9, Gardasil, Capvaxive |
| Genzyme Corporation | $20.47 | 2024 | |
| Sanofi Pasteur INC. | $18.75 | 2022 | |
| Kaleo, INC. | $18.26 | 2021 | |
| Amgen INC. | $17.27 | 2024 | Krystexxa |
| Paratek Pharmaceuticals, INC. | $16.00 | 2022 | |
| Novartis Pharmaceuticals Corporation | $15.92 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $15.27 | 2022 | |
| Antares Pharma, INC. | $15.09 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $13.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fenny Zen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.